Vascular Graft Solutions Wins FDA approval to Market the VIOLA™ Clampless Proximal Anastomosis System for CABG
Vascular Graft Solutions Wins FDA approval to Market the VIOLA™ Clampless Proximal Anastomosis System for CABG USA - English Share this article Share this article TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA™, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG). VIOLA™, now approved for sales in the US Neurocognitive dysfunction remains the most devastating perioperative complication of CABG and frequently...
Source: prnewswire.com